Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Exane BNP Paribas Upgrades Eramet to Outperform

Exane BNP Paribas analyst Sylvain Brunet upgrades Eramet (OTC:ERMAY) from Neutral to Outperform.

byBenzinga Newsdesk

October 6, 2021

1 minute read

Exane BNP Paribas analyst Sylvain Brunet upgrades Eramet (OTC:ERMAY) from Neutral to Outperform.

Piper Sandler Upgrades Biogen to Overweight, Raises Price Target to $450

By Benzinga Newsdesk

Today, 4:39 AM

Piper Sandler analyst Christopher Raymond upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $384 to $450.

BIIB

Overseas Shipholding Gr Q4 EPS $(0.03) Down From $(0.01) YoY, Sales $95.50M Down From $97.55M YoY

By Benzinga Newsdesk

Today, 4:39 AM

Overseas Shipholding Gr (NYSE:OSG) reported quarterly losses of $(0.03) per share. This is a 200 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $95.50 million in

OSG

Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz

By Vandana Singh

Today, 4:39 AM

Novartis AG (NYSE:NVS) has reported a core EPS of $1.56 in Q2 FY22 compared to $1.66 a year ago, beating the…

NVS

Jamie Dimon Not ‘Relevant’ To Decisions On Epstein’s Account, Says JPMorgan

By Shivdeep Dhaliwal

Today, 4:39 AM

JPMorgan Chase & Co (NYSE: JPM) called the U.S Virgin Islands’ demand that its CEO Jamie Dimon turn over more documents in a lawsuit related to disgraced financier Jeffrey Epstein’s

JPM

Exane BNP Paribas Upgrades Eramet to Outperform

Related Posts

Piper Sandler Upgrades Biogen to Overweight, Raises Price Target to $450

Overseas Shipholding Gr Q4 EPS $(0.03) Down From $(0.01) YoY, Sales $95.50M Down From $97.55M YoY

Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz

Jamie Dimon Not ‘Relevant’ To Decisions On Epstein’s Account, Says JPMorgan